Reliability and Validity of the 6‐Minute Walk Test in Hypophosphatasia
Open Access
- 7 December 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in JBMR Plus
- Vol. 3 (6) , e10131
Abstract
This investigation evaluated the reliability and validity of the 6‐Minute Walk Test (6MWT) in patients with pediatric hypophosphatasia (HPP). Children (aged 6 to 12 years; n = 11), adolescents (13 to 17 years; n = 4), and adults (18 to 65 years; n = 9) completed the 6MWT at screening and baseline in two clinical studies of asfotase alfa. Test‐retest reliability of the 6MWT, evaluated with Pearson's correlation coefficients (r) for screening versus baseline, was high for children (r = 0.95; p < 0.0001), adolescents (r = 0.81; p = 0.125), and adults (r = 0.94; p = 0.0001). The most conservative minimal clinically important differences, estimated using distribution‐based methods, were 31 m (children and adults) and 43 m (adolescents). In children, the 6MWT correlated significantly with scores on measures of skeletal disease, which included the Radiographic Global Impression of Change scale (r = 0.50; p < 0.0001) and the Rickets Severity Scale (r = −0.78; p < 0.0001), such that distance walked increased as the severity of skeletal disease decreased. Significant (p < 0.0001) correlations with the 6MWT distance walked were also observed for children with scores on parent‐reported measures of disability (r = −0.67), ability to function in activities of daily living (r = 0.71 to 0.77), and parent‐reported measures of pain (r = −0.39). In adolescents and adults, 6MWT distance walked correlated significantly (p < 0.05) with measures of lower extremity function (r = 0.83 and 0.60, respectively), total pain severity (r = −0.41 and −0.36, respectively), and total pain interference (r = −0.41 and −0.49, respectively). Collectively, these data indicate that the 6MWT is a reliable, valid measure of physical functioning in patients with pediatric HPP. © 2018 The Authors. JBMR Plus Published by Wiley Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research.Keywords
Funding Information
- Alexion Pharmaceuticals
This publication has 61 references indexed in Scilit:
- Reference values for the 6-minute walk test in healthy children and adolescents in SwitzerlandBMC Pulmonary Medicine, 2013
- The 6‐minute walk test and other clinical endpoints in duchenne muscular dystrophy: Reliability, concurrent validity, and minimal clinically important differences from a multicenter studyMuscle & Nerve, 2013
- Percent-Predicted 6-Minute Walk Distance in Duchenne Muscular Dystrophy to Account for Maturational InfluencesPLoS Currents, 2012
- Feasibility and effects of a physical exercise programme in adults with myotonic dystrophy type 1: A randomized controlled pilot studyJournal of Rehabilitation Medicine, 2011
- The 6-min walk distance in healthy subjects: reference standards from seven countriesEuropean Respiratory Journal, 2010
- Updating the Minimal Important Difference for Six-Minute Walk Distance in Patients With Chronic Obstructive Pulmonary DiseaseArchives of Physical Medicine and Rehabilitation, 2010
- Hypophosphatasia may lead to bone fragility: don’t miss itEuropean Journal of Pediatrics, 2008
- Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyThe Journal of Pediatrics, 2006
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- HypophosphatasiaPediatric Radiology, 1976